Latest Breaking News On - Urogen pharma ltd - Page 16 : comparemela.com

Form 8-K UroGen Pharma Ltd For: Jul 26

Form 8-K UroGen Pharma Ltd For: Jul 26
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Alexander parkUnited statesNew jerseyFred cohenDon kimLadenburg thalmannSecurities exchangeUrogen pharma ltdCompany quarterly report on formBofa securities incNasdaq stock marketDrug administrationExchange commissionSecurities exchange actPark driveZip code

Urogen Flat On Private Placement

Urogen Flat On Private Placement
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Great point partnersUrogen pharma ltdHorton capital partners fundUrogen flatPrivate placementGen pharmaAcorn bioventuresMonograph capital

URGN Stock Price | UroGen Pharma Ltd Stock Quote (U S : Nasdaq)

URGN | Complete UroGen Pharma Ltd. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Etby jaimy leeUrogen pharma ltdDrug administrationUrogen pharmaRgn analyst estimatesRgn earnings estimatesRgn share estimatesRgn analyst recommendationsRgn ratingsRogen pharma ltd analyst estimatesRogen pharma ltd earnings estimatesRogen pharma ltd analyst recommendationsRogen pharma ltd analyst ratings

Why UroGen Pharma Stock Is Gaining Today? - UroGen Pharma (NASDAQ:URGN)

UroGen Pharma Ltd (NASDAQ: URGN) shares are surging after the company released topline data from its Phase 3 trials ATLAS and ENVISION studying UGN-102 (mitomycin) for intravesical solution in patients with low-grade, intermediate-risk non-muscle invasive 

Urogen pharma ltdUrogen pharmaNew drug application

UroGen Pharma Up 37% On Phase 3 Trials Meeting Endpoints

Shares of UroGen Pharma Ltd. (URGN) are up 37% on Thursday after the company announced that the data collected from its phase 3 trials, namely ATLAS and ENVISION, which studied intravesical solutions for patients with LG-IR-NMIBC using UGN-102, have successfully met their primary endpoints.

Urogen pharma ltdUrogen pharmaPrivate placement